Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8554822 | 0.93 | MAPK1 (0.64) | NPC1RAB9AMEN1KMT2AHPGD | |
| SCHEMBL13753876 | 0.91 | MEN1 (0.56) | NPC1RAB9AMEN1KMT2AHPGD | |
| Ammonia Solution, Strong SCHEMBL11688841 | 0.90 | MEN1 (0.55) | NPC1RAB9AMEN1KMT2AHPGD | |
| SCHEMBL30028618 | 0.89 | MEN1 (0.58) | NPC1RAB9AMEN1KMT2AHPGD | |
| Hydrochloric Acid SCHEMBL27511963 | 0.88 | MEN1 (0.57) | NPC1RAB9AMEN1KMT2AHPGD | |
| SCHEMBL2815923 | 0.87 | KDM4E (0.65) | NPC1RAB9AMEN1KMT2AHPGD | |
| SCHEMBL23642995 | 0.87 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2AHPGD | |
| SCHEMBL12251449 | 0.87 | MEN1 (0.63) | NPC1RAB9AMEN1KMT2AHPGD | |
| SCHEMBL23643207 | 0.87 | CSF1R (0.55) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13917946 | 0.87 | ABCB1 (0.62) | NPC1RAB9AMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4206184-A1 | PHENOL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-05 | — | — | EP | disclosed |
| WO-2021067490-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2021-04-08 | — | — | WO | disclosed |
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. | 2019-04-18 | — | — | US | disclosed |
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. | 2019-04-18 | — | — | US | disclosed |
| US-10195189-B2 | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds | Prosetta Antiviral, Inc. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10195189-B2 | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds | Prosetta Antiviral, Inc. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| EP-1389216-B1 | AVERMECTINS SUBSTITUTED IN THE 4\"-POSITION HAVING PESTICIDAL PROPERTIES | MERIAL INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED | 2008-08-21 | — | — | US | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7250432-B2 | Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-31 | — | — | US | disclosed |
| WO-2006126751-A1 | NEW DIARYL-ISOXAZOLE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME FOR THE PREVENTION AND THE TREATMENT OF CANCERS | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-11-30 | — | — | WO | disclosed |
| US-20050131036-A1 | Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-06-16 | — | — | US | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-0617022-B1 | 6,7, dialkoxy-3,4-dihydroisoquinolin-8-ol, process for preparation thereof and process for preparation of 6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolin-8-ol using the compound | BANYU PHARMA CO LTD (JP) | 1998-02-11 | — | — | EP | disclosed |
| US-5498717-A | CHEMICAL INTERMEDIATES FOR PRODUCING ANTITUMOR POTENTIATORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-03-12 | — | — | US | disclosed |
| US-5446164-A | Regioselective cyclization of phenethylamide derivative in presence of phosphoric acid halide, reducing formed compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | NPC1 245/4885RAB9A 1408/4885MEN1 3715/4885 |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | NPC1 1989/4885RAB9A 3570/4885MEN1 1419/4885 |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | NPC1 1354/4885RAB9A 2212/4885MEN1 3926/4885 |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | PARP1, PARP11, PARP2 | NPC1 4492/4885RAB9A 4538/4885MEN1 3842/4885 |
| US-10195189-B2 | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds | MAVS, EIF2AK2, POLRMT | NPC1 245/4885RAB9A 1408/4885MEN1 3715/4885 |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | NPC1 245/4885RAB9A 1408/4885MEN1 3715/4885 |
| US-20050131036-A1 | Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers | UACA, SQLE, ALDH1A2 | NPC1 3303/4885RAB9A 1018/4885MEN1 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.